Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Invest Dermatol. 2019 Jan 11;139(6):1254–1263. doi: 10.1016/j.jid.2018.12.017

Table 1.

Experimental groups of mice by genotype and treatment*

Genotype No. of mice examined (M+F) Injected with Dose per mouse (IFU) Frequency of injections Age at time of injection Duration Age at time of analysis

Set 1 (Time course)
C57BL/6J 6 (3+3) NA NA NA NA NA 10w
Abcc6−/−Rag1−/− 4 (2+2) NA NA NA NA NA 10w
Abcc6−/−Rag1−/− 6 (2+4) Ad5-CMV-hABCC6 4×108 1 6w 1w 7w
Abcc6−/−Rag1−/− 6 (1+5) Ad5-CMV-hABCC6 4×108 1 6w 2w 8w
Abcc6−/−Rag1−/− 4 (2+2) Ad5-CMV-hABCC6 4×108 1 6w 4w 10w
Abcc6−/−Rag1−/− 5 (1+4) Ad5-CMV-hABCC6 4×108 1 6w 6w 12w
Abcc6−/−Rag1−/− 4 (2+2) Ad5-CMV-hABCC6 4×108 1 6w 8w 14w
Set 2 (Dose response)
C57BL/6J 6 (3+3) NA NA NA NA NA 10w
Abcc6−/−Rag1−/− 4 (2+2) NA NA NA NA NA 10w
Abcc6−/−Rag1−/− 8 (4+4) Ad5-PL-hABCC6 1×109 1 6w 4w 10w
Abcc6−/−Rag1−/− 8 (5+3) Ad5-CMV-hABCC6 1×109 1 6w 4w 10w
Abcc6−/−Rag1−/− 8 (5+3) Ad5-CMV-hABCC6 4×108 1 6w 4w 10w
Set 3 (Prevention study)
C57BL/6J 7 (2+5) NA NA NA NA NA 14w
C57BL/6J 9 (4+5) NA NA NA NA NA 18w
Abcc6−/−Rag1−/− 14 (9+5) NA NA NA NA NA 14w
Abcc6−/−Rag1−/− 13 (9+4) NA NA NA NA NA 18w
Abcc6−/−Rag1−/− 10 (6+4) Ad5-CMV-hABCC6 4×108 1 6w 8w 14w
Abcc6−/−Rag1−/− 9 (5+4) Ad5-CMV-hABCC6 4×108 2 6w, 10w 4w, 4w 14w
Abcc6−/−Rag1−/− 13 (9+4) Ad5-CMV-hABCC6 4×108 3 6w, 10w, 14w 4w, 4w, 4w 18w
Set 4 (Reversal study)
C57BL/6J 6 (3+3) NA NA NA NA NA 47w
Abcc6−/−Rag1−/− 8 (3+5) Ad5-PL-hABCC6 4×108 1 43w 4w 47w
Abcc6−/−Rag1−/− 8 (3+5) Ad5-CMV-hABCC6 4×108 1 43w 4w 47w
*

Mice with desired genotypes were injected with either Ad5-PL-hABCC6 or Ad5-CMV-hABCC6 adenovirus at designated frequency and duration as indicated in the table. The mice were sacrificed for determination of human ABCC6 expression in mouse liver, PPi levels in plasma and the degree of ectopic mineralization in the muzzle skin. M, male; F, female; w, weeks.